Nektar Therapeutics Stock
-
Your prediction
Nektar Therapeutics Stock
Nektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Pros and Cons of Nektar Therapeutics in the next few years
Pros
Cons
Performance of Nektar Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Nektar Therapeutics | - | - | - | - | - | - | - |
| Ligand Pharmaceuticals | 0.970% | 1.980% | 4.569% | 120.321% | 24.096% | 202.941% | 122.270% |
| United Therapeutics | -0.460% | -1.202% | -6.048% | 66.923% | 11.608% | 133.431% | 228.897% |
| Ionis Pharmaceuticals Inc. | 0.220% | -1.464% | 0.466% | 108.654% | -4.915% | 59.398% | 127.696% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.In general, Nektar Therapeutics (NKTR) from the Biotechnology & Medical Research industry presents an interesting financial profile. The company seems to have struggled with net income over the last few years but maintains a consistent cash position and sizeable investments. Below is a comprehensive analysis of the company's financials, including notable pros and cons to consider.
Solid Cash Position: NKTR has maintained a reasonably strong cash position throughout the years, with an end-period cash balance of $102.6 million in 2020, $25.2 million in 2021, and $88.2 million in 2022. As of Q1 2023, the cash balance stands at $76.9 million, indicating that the company has been able to consistently generate and preserve cash.
Growing Total Assets: The company registered an increase in total assets from $1.54 billion in 2020 to $1.12 billion in 2021, although there was then a decrease to $710.6 million in 2022. Despite the recent decline, the overall trend in asset growth signifies that the business is expanding.
Comments
News
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch
On May 15, 2026, Prosight Management disclosed a buy of 180,367 shares of Nektar Therapeutics (NASDAQ:NKTR), an estimated $10.27 million trade based on quarterly average pricing.
According to a
Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares
According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Patient Square Capital LP disclosed the purchase of 210,000 shares of Nektar Therapeutics (NASDAQ:NKTR). The
Nektar Therapeutics Q1 Earnings Call Highlights
Nektar Therapeutics (NASDAQ:NKTR) outlined plans to advance its lead regulatory T-cell (Treg) therapy rezpegaldesleukin (REZPEG) into
